GlassScriptPhysician profile
Joseph A Deblasio
NPI 1871856864
$4,703.57
in general payments reported to CMS, 2019-2025
22 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $542 · 2021: $936 · 2022: $1,170 · 2023: $963 · 2024: $516 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,433.65 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $771.59 | 2020-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $394.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Genentech USA, INC. | $240.06 | 2019-2020 | |
| Lilly USA, LLC | $119.69 | 2021-2024 | Jardiance, Zepbound |
| Regeneron Healthcare Solutions, INC. | $118.39 | 2019 | |
| Exact Sciences Corporation | $92.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| W. L. Gore & Associates, INC. | $92.36 | 2021 | |
| Pfizer INC. | $83.72 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.99 | 2025 | |
| Astellas Pharma US INC | $60.51 | 2023 | Veozah, Myrbetriq |
| Abbott Laboratories | $49.05 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Bausch Health US, LLC | $41.83 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.62 | 2022-2023 | Synjardy, Jardiance |
| Dexcom, INC. | $19.05 | 2025 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $14.86 | 2022 | |
| Sanofi Pasteur INC. | $14.36 | 2023 | |
| Almatica Pharma LLC | $14.26 | 2022 | |
| Embecta Corp. | $13.68 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Amneal Pharmaceuticals LLC | $13.49 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.01 | 2023 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $11.35 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Deblasio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.